Objective This study aims to explore whether Loureirin A can mitigate neutrophil-related pathology and vascular damage in a photothrombotic stroke model.Methods C57BL/6J mice were divided into three groups:sham-operated,model,and Loureirin A administered(Model+Loureirin A,10 mg·kg-1).A mouse model of focal cerebral ischemia was established using photothrombosis(PT),and the administration of Loureirin A commenced one day post-surgery via intraperitoneal injection for three consecutive days.Neurological function was assessed in the mice 24 h post-PT modeling,while the infarction rate was evaluated through TTC staining three days post-PT modeling.MPO-positive cell infiltration in the peri-infarct cortex was detected by immunohistochemistry.The reactive oxygen species(ROS)content was observed via immunofluorescence staining.Cerebral blood flow in mice was measured by laser speckle imaging.The expression of tight junction proteins ZO-1(Zonula occludens-1),Occludin,and matrix metalloproteinase-9(MMP-9)was detected by immunoblotting.Vascular permeability was assessed by 40 kDa FITC-Dextran,and peri-infarct vascular density was detected by 2000 kDa FITC-Dextran.Results Loureirin A markedly decreased the cerebral infarction rate and the extent of neurological functional impairment,and enhancing blood perfusion.Pathological examinations revealed that Loureirin A lessened neutrophil infiltration,reduced intracellular ROS,and increased the protein expression of ZO-1 and Occludin,which are critical components of the blood-brain barrier.Concurrently,it downregulated Matrix Metalloproteinase-9(MMP-9).Furthermore,Loureirin A diminished the leakage of extracellular 40 kDa dextran,bolstered peri-infarct cerebral vascular perfusion,and mitigated vascular injury.Conclusion Loureirin A can inhibit neutrophil infiltration and vascular injury after cerebral ischemia.

Objective This study aims to explore whether Loureirin A can mitigate neutrophil-related pathology and vascular damage in a photothrombotic stroke model.Methods C57BL/6J mice were divided into three groups:sham-operated,model,and Loureirin A administered(Model+Loureirin A,10 mg·kg-1).A mouse model of focal cerebral ischemia was established using photothrombosis(PT),and the administration of Loureirin A commenced one day post-surgery via intraperitoneal injection for three consecutive days.Neurological function was assessed in the mice 24 h post-PT modeling,while the infarction rate was evaluated through TTC staining three days post-PT modeling.MPO-positive cell infiltration in the peri-infarct cortex was detected by immunohistochemistry.The reactive oxygen species(ROS)content was observed via immunofluorescence staining.Cerebral blood flow in mice was measured by laser speckle imaging.The expression of tight junction proteins ZO-1(Zonula occludens-1),Occludin,and matrix metalloproteinase-9(MMP-9)was detected by immunoblotting.Vascular permeability was assessed by 40 kDa FITC-Dextran,and peri-infarct vascular density was detected by 2000 kDa FITC-Dextran.Results Loureirin A markedly decreased the cerebral infarction rate and the extent of neurological functional impairment,and enhancing blood perfusion.Pathological examinations revealed that Loureirin A lessened neutrophil infiltration,reduced intracellular ROS,and increased the protein expression of ZO-1 and Occludin,which are critical components of the blood-brain barrier.Concurrently,it downregulated Matrix Metalloproteinase-9(MMP-9).Furthermore,Loureirin A diminished the leakage of extracellular 40 kDa dextran,bolstered peri-infarct cerebral vascular perfusion,and mitigated vascular injury.Conclusion Loureirin A can inhibit neutrophil infiltration and vascular injury after cerebral ischemia.

The EtOH extracts of the whole plants of afforded 17 new jatrophane diterpenoid esters, helioscopianoids A-Q (-), along with eight known compounds (-). Their structures were elucidated by extensive spectroscopic methods and Mo(OAc)-induced ECD analysis, and the structures of compounds , , and were confirmed by X-ray crystallography. Compounds - were evaluated for inhibitory effects on P-glycoprotein (P-gp) in an adriamycin (ADM)-resistant human breast adenocarcinoma cell line (MCF-7/ADR) and neuroprotective effects against serum deprivation-induced and rotenone-induced PC12 cell damage. Compounds and increased the accumulation of ADM in MCF-7/ADR cells by approximately 3-fold at a concentration of 20 μmol/L. Compound could attenuate rotenone-induced PC12 cell damage, and compounds , , and showed neuroprotective activities against serum deprivation-induced PC12 cell damage.

Aim To research the synergistic effect of hyperlipoproteinemia and Aβ in the processing of Alzheimer′s disease.Methods Seventy SD rats were randomly divided into seven groups, and dealt with D-gal(hypodermic injection), hyperlipemia diet, microinjection into both side of CA1 section in hippocampus, independently.Morris water maze(MWM) test was used to evaluate the spatial memory impairments.Tau and tau(pThr181) pathology in the hippocampus were detected using Western blot and immunohistochemistry.Nissl′s staining was used to detect cell apoptosis.Results Aβ25-35-treated rats showed significant impairments of spatial memory in MWM test, especially in the group of D-gal+Aβ25-35+HLD(P<0.01).Furthermore, these rats treated with Aβ25-35, D-gal, and hyperlipemia diet, exhibited significantly increased phosphorylation of tau, particularly in the Thr181 site.Conclusion Hyperlipoproteinemia is the risk factor for older person, which could strengthen the toxic effect of Aβ, and promote phosphorylation of tau.

Discovery of noncoding RNA(ncRNA)over the past decade has reflected a paradigm shift of traditional RNA research. There is evidence that RNA can function not only as a messenger between DNA and protein,but as a regulator of genome organization and gene expression,which is increasingly elaborate in complex organisms. ncRNA seems to operate at many levels,however,in?cluding the physiological and pathological status. The research of ncRNA in pharmacology has not been summarized before. Here,we reviewed the emergence of the ncRNA in the research of pharma? cology,such as acting as biomarkers and medical targets. Besides,we mentioned their role in drug resistance and drug addiction in order to highlight the significant role of ncRNA in pharmacology.

Since Parkin was confirmed by the Japanese scholar to be associated with juvenile Parkinson′s disease, it has come to be the focus of the scholars and a lot of researches have been made on it. Apart from Parkinson′s disease, many other disea-ses have also been proved to be associated with the role of Parkin and its interaction with protein substrates, especially in various kinds of cancer diseases and leukemia. This paper focuses on the latest research about Parkin and its development in tumor diseases and leukemia.

Aim To investigate the role of chemokine-like factor 1 ( CKLF1 ) in SH-SY5 Y cell migration and its molecular regulatory mechanism. Methods SH-SY5Y cells were stimulated with CKLF1 for 0. 5 h, 2 h, 8 h and 24 h, respectively. The migration distance and the percentage of migration cells were recorded by CELLocate analysis. The phosphorylation of focal ad-hesion kinase ( FAK) at Tyr-397 site was detected by Western blot analysis. By chemotaxis assays, we con-firmed the chemotaxis of CKLF1. Furthermore, FAK inhibitor PF-573228 and PLCγ inhibitor U73122 were used for the research of molecular regulatory mecha-nisms involved. Results CKLF1 promoted cell migra-tion and induced a strong increase in the phosphoryla-tion level of FAK-pY397 , which were significantly at-tenuated by the presence of U73122 ( a specific inhibi-tor for PLCγ) . In addition, the chemotaxis of CKLF1 was obviously blocked by the FAK inhibitor PF-573228 . Conclusion CKLF1 induces SH-SY5 Y cell migration via PLCγ/FAK signaling pathway.

Calcium/calmodulin-dependent protein kinase Ⅱ(CaMKⅡ),which is an important protein kinase involved in learning and memory,is found in most tissues,but it is present in especially high concentrations in neurons.The relatively high expression of CaMKⅡin nervous system suggests it plays an im-portant role in the function of nervous system.This paper re-views the research development of the molecular structure of CaMKⅡ and its autophosphorylation,subcellular localization and its role in synaptic plasticity.

Pyk2(Proline-rich tyrosine kinase 2) is an important member of focal adhesion kinase family. Pyk2 is highly ex-pressed in the central nervous system and the hematopoietic sys-tem . Pyk 2 can trigger a variety of SH 2 domain-containing pro-
teins to phosphorylate their substrates, thus it can participate in the regulations including ion channel activation, stress response, cell adhesion, cytoskeleton reorganization, vesicle transport and so on. Through the regulations above, the ability of cell migra-tion, survival, proliferation changes accordingly, suggesting that Pyk2 in many important regulatory processes may become a tar-get for clinical effects. Current drug development for Pyk2 main-
ly focuses on cancer, osteoporosis and immune response. This review illustrates the domain structure, regulatory mechanisms, potential drug targets, and the drug development of Pyk2 based on the above three fields, which will provide a theoretical basis for clinical treatment.

Aim To study the screening of the nucleo-tide sequences might be affected by α-syn in vitro. Methods The nucleotide sequences were synthesized according to the feature of base composition, and then mixed with the α-syn-GFP. The CD was used to ana-lyse the changes of the peak. Result The peak of the CD changed greatly when the α-syn-GFP mixed with the GC-box like sequence. Conclusion The α-syn-GFP might affect the GC-box like sequence after trans-located into the nuclei. Then, it plays a role in physio-logical and pathological conditions by affecting the reg-ulation of gene expression.